Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
To the best of our knowledge there
2024-05-31
To the best of our knowledge, there have been only a few reports on antiangiogenic activities about C. sanki, and its antiangiogenic constituents as well as its mechanism of action are worthy of further exploring and studying. Therefore, we carried out a bioassay-guided investigation of C. sanki in
-
Use of RASB is associated
2024-05-31
Use of RASB is associated with potential concerns about side effects such as acute kidney injury or hyperkalemia, and clinicians are reluctant to prescribe RASB in patients with severe renal dysfunction (estimated GFR Conclusions Conflict of interest Acknowledgement Introduction Renin-an
-
br Angiotensin receptor neprilysin inhibitors Sacubitril val
2024-05-31
Angiotensin receptor-neprilysin inhibitors Sacubitril/valsartan is the first-in-class ARNI, comprising of molecular moieties of valsartan (ARB) and a neprilysin inhibitor prodrug, sacubitril (AHU377) [51]. Upon ingestion, sacubitril is rapidly metabolised into an active neprilysin inhibitor, sacu
-
Luo Dehm Raj Luo Attard Balk Bevan
2024-05-31
Luo, Dehm, Raj. Luo, Attard, Balk, Bevan, Burnstein, Cato, Cherkasov, De Bono, Dong, Gao, Gleave, Heemers, Kanayama, Kittler, Lang, Lee, Logothetis, Matusik, Plymate, Sawyers, Selth, Soule, Tilley, Weigel, Zoubeidi, Dehm, Raj. Luo, Attard, Balk, Bevan, Burnstein, Cato, Cherkasov, De Bono, Dong,
-
The advantage of active immunotherapy
2024-05-31
The advantage of active immunotherapy is long-term antibody production from short-term drug administration at limited cost. Conversely, immune response may be inconsistent or lacking, especially in older individuals, and adverse reactions—if immunologically based—may also be long-lasting. Initial ex
-
The current study was designed
2024-05-31
The current study was designed to investigate the effects of the 12/15-LOX inhibitor, LOXBlock-1 (LB1) in mice using a FeCl3-induced distal MCAO model, and to test its utility in conjunction with subsequent thrombolysis with tPA, which is to date the only FDA-approved drug for acute stroke treatment
-
br Methods The study population included neuropathologically
2024-05-31
Methods The study population included 64 neuropathologically confirmed AD patients (6 male, 58 female) that were recruited into a longitudinal follow-up study of patients with dementia of Alzheimer’s type from the geriatric department of Harjula Hospital in Kuopio, Finland. At baseline the patien
-
When a clinician diagnoses a person with AD the
2024-05-31
When a clinician diagnoses a person with AD, the person is transformed into a patient with the disease. The person is a member of a patient group associated with behaviors, abilities, and experiences related both formally and informally to the diagnosis [10]. The diagnostic label implies what signs
-
For the time being fluorescent in situ hybridization FISH
2024-05-31
For the time being, fluorescent in situ hybridization (FISH) remains the ‘gold standard’ for ALK rearrangements diagnosis but immunohistochemistry has become a widely used pre-screening tool and the FDA recently approved the Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Tucson, AZ) as a com
-
The current guidelines are designed to
2024-05-31
The current guidelines are designed to optimize the detection of IHC+FISH+ cases, most of which (but not all encountered in our study) being classically good responders to crizotinib therapy (resistance mechanisms to crizotinib therapy were not investigated in our study). In addition to the current
-
Interestingly as observed with Treg cells adenosine can regu
2024-05-31
Interestingly, as observed with Treg cells, adenosine can regulate the function of Breg cells, a subset of immunosuppressive cells that support immunological tolerance [115]. In particular, Bregs were able to regulate both their own function and T cell activity via an adenosine signaling originating
-
Our second patient years old male a
2024-05-31
Our second patient, 42years old male, a farmer, was all right when he went to sleep, but noticed drooping of eyelids and swallowing difficulty when he woke up. He later developed flaccid weakness of all four limbs and was quadriplegic when he was wheeled into the emergency room. He was tachypneic an
-
br Materials and methods br Functional demonstrations
2024-05-31
Materials and methods Functional demonstrations of ACh/GABA cotransmission The cotransmission of GABA and ACh has been best characterized in starburst amacrine cells (SACs) of the retina. SACs are a subtype of amacrine cell, a diverse set of retinal interneurons that are crucial for processing
-
br Conclusion To conclude it would be fair to
2024-05-31
Conclusion To conclude, it would be fair to say that the research efforts on FLAP inhibitors for intervening with LT biosynthesis have reached to a considerably advanced state during the last decade as a result of growing interest from both pharmaceutical industry and academia [4], [37], [38]. Du
-
Introduction Lysophosphatidic acid LPA is a key serum
2024-05-31
Introduction Lysophosphatidic pathways cu (LPA) is a key, serum-borne phospholipid, regulating a number of cellular processes such as proliferation, migration and differentiation through its interaction with G-protein coupled receptors. LPA receptor signaling has been implicated in several disease
15778 records 133/1052 page Previous Next First page 上5页 131132133134135 下5页 Last page